Extract

To provide required access of investigational product (darbepoetin alfa) beyond the end of active treatment period of the Darbepoetin alfa MDS 20090160 study for subjects that have continued demonstration of benefit from darbepoetin alfa treatment and to describe the safety of longer-term use in this patient population.

Inclusion criteria

• Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Links

• ictrp
• euctr